EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity

Milton Packer iD, Michael R Zile, Christopher M Kramer, Seth J Baum, Sheldon E Litwin, Venu Menon, Junbo Ge, Govinda J Weerakkody, Yang Ou, Mathijs C Bunck, Karla C Hurt, Masahiro Murakami und 2 weitere

New England Journal of Medicine · 30.01.2025 · 392 (5) · 427-437

DOI: 10.1056/nejmoa2410027 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 30.01.2025. Verfasst von Milton Packer und 13 weiteren Autor:innen. Beteiligte Einrichtung: From Baylor University Medical Center, Dallas (M.P.); Imperial College, London (M.P.); RHJ Department of Veterans Affairs, Health System and Medical …. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Heart Failure, Obesity, Tirzepatide. Die Arbeit wurde bisher 1044-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss, but data are lacking with respect to its effects on cardiovascular outcomes. METHODS: In this international, double-blind, randomized, placebo-controlled trial, we randomly assigned, in a 1:1 ratio, 731 patients with heart failure, an ejection fraction of at least 50%, and a body-mass index (the weight in kilograms divided by the square of the height in meters) of at least 30 to receive tirzepatide (up to 15 mg subcutaneously once per week) or placebo for at least 52 weeks. The two primary end points were a composite of adjudicated death from cardiovascular causes or a worsening heart-failure event (assessed in a time-to-first-event analysis) and the change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating better quality of life). RESULTS: A total of 364 patients were assigned to the tirzepatide group and 367 to the placebo group; the median duration of follow-up was 104 weeks. Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P = 0.026). Worsening heart-failure events occurred in 29 patients (8.0%) in the tirzepatide group and in 52 patients (14.2%) in the placebo group (hazard ratio, 0.54; 95% CI, 0.34 to 0.85), and adjudicated death from cardiovascular causes occurred in 8 patients (2.2%) and 5 patients (1.4%), respectively (hazard ratio, 1.58; 95% CI, 0.52 to 4.83). At 52 weeks, the mean (±SD) change in the KCCQ-CSS was 19.5±1.2 in the tirzepatide group as compared with 12.7±1.3 in the placebo group (between-group difference, 6.9; 95% CI, 3.3 to 10.6; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1Heart FailureObesityTirzepatideAgedFemaleHumansMaleMiddle AgedBody Mass IndexCardiovascular DiseasesDouble-Blind MethodKaplan-Meier EstimateQuality of LifeStroke VolumeFollow-Up StudiesTreatment Outcome

Substanzen

Glucagon-Like Peptide 1Tirzepatide

Autor:innen und Institutionen

  • From Baylor University Medical Center, Dallas (M.P.); Imperial College, London (M.P.); RHJ Department of Veterans Affairs, Health System and Medical University of South Carolina, Charleston (M.R.Z., S.E.L.); the Cardiov…

ORCID-Profile: Milton Packer

Förderung

  • Eli Lilly and Company

Zitieren

APA

Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., Hurt, K. C., Murakami, M., Borlaug, B. A., & SUMMIT Trial Study Group (2025). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine, 392(5), 427-437. https://doi.org/10.1056/nejmoa2410027

Vancouver

Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 2025;392(5):427-437. doi:10.1056/nejmoa2410027

BibTeX
@article{Packer2025,
  author = {Packer, Milton and Zile, Michael R and Kramer, Christopher M and Baum, Seth J and Litwin, Sheldon E and Menon, Venu and Ge, Junbo and Weerakkody, Govinda J and Ou, Yang and Bunck, Mathijs C and Hurt, Karla C and Murakami, Masahiro and Borlaug, Barry A and SUMMIT Trial Study Group, SUMMIT Trial Study Group},
  title = {Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {5},
  pages = {427--437},
  doi = {10.1056/nejmoa2410027}
}
Kostenlos starten →